INBX
Inhibrx Biosciences, Inc.
$134.35
+7.89%
2026-05-08
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Key Fundamentals
Forward P/E
-43.76
EPS (TTM)
$-9.03
ROE
-197.8%
Revenue Growth (YoY)
-100.0%
Profit Margin
0.0%
Debt/Equity
1338.82
Price/Book
222.81
Market Cap
$1.78B
Avg Volume (10D)
514K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$155.29
60D Low
$57.41
Avg Volume
320K
Latest Close
$134.35
Get breakout alerts for INBX
Sign up for Breakout Scanner to receive daily notifications when INBX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Inhibrx Biosciences, Inc. (INBX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors INBX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. INBX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.